Quince Therapeutics Inc.

NASDAQ: QNCX · Real-Time Price · USD
1.70
0.02 (1.19%)
At close: Aug 15, 2025, 3:59 PM
1.62
-4.71%
After-hours: Aug 15, 2025, 07:43 PM EDT

Quince Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
186K 322K 175K 344K
Gross Profit
-186K -322K -175K -344K
Operating Income
-57.28M -34.62M -52.02M -90.32M
Interest Income
2.93M 3.48M 1.07M 620K
Pretax Income
-56.74M -31.58M -51.94M -89.94M
Net Income
-56.83M -31.39M -51.66M -89.94M
Selling & General & Admin
17.58M 15.39M 26.01M 29.52M
Research & Development
18.59M 9.45M 25.18M 60.8M
Other Expenses
-186K -522K -1.27M n/a
Operating Expenses
35.98M 24.32M 49.91M 90.32M
Interest Expense
n/a n/a 568K n/a
Selling & Marketing Expenses
n/a -2.3M n/a n/a
Cost & Expenses
36.17M 24.64M 50.09M 90.32M
Income Tax Expense
87K -197K -284K n/a
Shares Outstanding (Basic)
43.26M 37.24M 33.5M 29.72M
Shares Outstanding (Diluted)
43.26M 37.24M 33.5M 29.72M
EPS (Basic)
-1.31 -0.84 -1.54 -3.03
EPS (Diluted)
-1.31 -0.84 -1.54 -3.03
EBITDA
-56.55M -31.26M -49.89M -89.97M
EBIT
-56.74M -31.58M -50.09M -90.32M
Depreciation & Amortization
186K 322K 204K 344K